$0.58+3.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
The quarter ending September 30, 2022, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2022 | 3 months toJun 30, 2021 | Change |
|---|---|---|---|
| Total Revenue | $165M | $0.00 | — |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Biomea Fusion, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Across our portfolio, we continue to execute with focus and discipline, with all of our key clinical programs progressing on track toward important upcoming milestones, while maintaining a disciplined approach to managing our cash burn,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure. Visit us at biomeafusion.com and follow us on LinkedIn , X and Facebook .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Biomea Fusion, Inc.’s Item 2.02 8-K filed May 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.